GAITHERSBURG, Md., Aug. 5 /PRNewswire/ -- Panacea Pharmaceuticals, Inc.
today announced the appointment of Suzanne Sensabaugh as Vice President,
Regulatory Affairs. Ms. Sensabaugh will assume responsibility for
formulating strategies and managing all U.S. and foreign regulatory filings
for the Company's therapeutic and diagnostic products. This role is of
critical importance as the Company prepares to file applications with the
U.S. Food and Drug Administration for approval of its prostate and lung
cancer diagnostic tests, and to begin clinical trials of its cancer and
neuroprotectant therapeutic products within the next 12 months.
"We are very pleased to welcome Suzanne to the team at Panacea",
commented Hossein Ghanbari, Ph.D., Chairman, CEO and Chief Scientific
Officer at Panacea Pharmaceuticals. "Suzanne brings a breadth of regulatory
experience related to therapeutic products and particularly monoclonal
antibodies, in industry and with the FDA. Her experience is particularly
important as we progress PAN-622, our lead cancer therapeutic which is an
all-human sequence monoclonal antibody, toward Phase I clinical trials in
early 2009."
Just prior to joining Panacea, Ms. Sensabaugh held the position of Vice
President, Biopharmaceutical Development, MDS Pharma Services, where she
was responsible for managing and directing the consulting group in
Development & Regulatory Services and providing professional guidance to
clients. She has more than 10 years of experience with the Center for
Biologics Evaluation and Research (CBER) within the U.S. Food and Drug
Administration as a researcher, product reviewer, and inspector for
biologics. She also was involved in the development and implementation of
SOPs, guidance, regulations, and laws. Ms. Sensabaugh began her industry
career as Associate Director, Regulatory Affairs, at Genzyme Corporation
where she directed, planned, and implemented global regulatory activities.
She has held senior positions as Vice President, Regulatory Affairs &
Quality, at SICOR Inc., Biotechnology Division, where she was responsible
for global regulatory affairs, quality assurance and control, and Vice
President, Regulatory Affairs, and Senior Director for Global Biogenerics,
at Teva Pharmaceutical Industries Ltd., where she developed regulatory
strategy and submissions for biotechnology products. Ms. Sensabaugh
received her MBA from Duke University, MS in Biotechnology from Johns
Hopkins University, and BS in Zoology from the University of Maryland. She
teaches clinical development of drugs and biologics at Johns Hopkins
University.
"I am excited to add Suzanne to our team. Her expertise and experience
will be critically important as we move toward clinical development of our
cancer and CNS therapeutic products," commented Stephen N. Keith, MD, MSPH,
President and Chief Operating Officer. "We will continue to strengthen our
management team, looking to add scientific and managerial staff with
experience in biotechnology and pharmaceuticals. I am confident that
Suzanne will play an important role in facilitating the success of our
therapeutic and diagnostic products."
About Panacea's Oncology Platform
In addition to the cancer therapeutic PAN-622, Panacea offers: PC
Detect(R), a diagnostic test used in conjunction with PSA and digital
rectal exam to identify patients with prostate cancer; LC Detect(sm), a
diagnostic test to aide in the detection of patients with lung cancer; BC
Detect(sm), a diagnostic test to aide in the detection of recurrence of
breast cancer; CC Detect(sm), a diagnostic test to aide in the detection of
colo-rectal cancer; and TK Sense(R), which determines whether white blood
cells from patients with chronic myelogenous leukemia (CML) are sensitive
or resistant to imatinib, the therapy of first choice for CML patients,
prior to initiation of therapy. Each of these tests is offered as a
laboratory service performed by Panacea Laboratories
(http://www.panacea-labs.com), a division of Panacea Pharmaceuticals, Inc.
About Panacea Pharmaceuticals, Inc.
Panacea Pharmaceuticals, Inc. is a privately-held biopharmaceutical
company focused on the development and commercialization of therapeutics
and diagnostics for diseases with substantial, unmet clinical needs. The
Company's product development strategy is based on novel therapeutic agents
and approaches for cancer treatment, as well as acute and chronic
neurodegenerative conditions, such as hypoxia-induced neurological insult,
Parkinson's Disease, and Alzheimer's Disease. Panacea has an extensive
patent portfolio covering its neurodegenerative and oncology technologies.
Panacea Laboratories is a division of Panacea Pharmaceuticals, Inc.
Additional information about the Company is available at
http://www.PanaceaPharma.com.
Except for historical information presented in this press release,
matters discussed herein may constitute "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of 1995.
Forward- looking statements are based on the opinions and estimates of
management only as of the date of this release and are subject to certain
risks and uncertainties that could cause actual results to differ
materially from any future results, performance, or achievements expressed
or implied by such statements. Factors that might cause such a difference
include, but are not limited to, uncertainties related to our access to
capital, the progress, costs, and results of any clinical trials undertaken
by us, progress of our research and development projects, and uncertainties
related to whether our product candidates would ultimately achieve
commercial success. We do not undertake any obligation to update publicly
any forward-looking statement, whether as a result of new information,
future events, or otherwise unless required by law.
SOURCE Panacea Pharmaceuticals, Inc.
 back to top
Related links:
http://www.panaceapharma.com
http://www.panacea-labs.com
CONTACT:
Stephen N. Keith, MD, MSPH, President & Chief
Operating Officer of Panacea Pharmaceuticals, Inc.,
+1-240-243-8000; Fax +1-240-465-0450, skeith@panaceapharma.com
|
